A Microfluidic Computational Fluid Dynamics Model for Cellular Interaction Studies of Sickle Cell Disease Vaso-Occlusions

Publication date: Available online 5 August 2020Source: Microvascular ResearchAuthor(s): Ian P. Blakely, Renita E. Horton
Source: Microvascular Research - Category: Biochemistry Source Type: research

Related Links:

CONCLUSIONS: PheWAS is a viable tool for calculating risk associated with any biomarker. The current analysis provide a new approach to generating hypotheses and understanding the breadth of health disparities. Future analyses will further explore causality, risk factors, and potential confounders not accounted for here. PMID: 32958289 [PubMed - as supplied by publisher]
Source: Journal of the National Medical Association - Category: General Medicine Tags: J Natl Med Assoc Source Type: research
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Short Communication Source Type: research
Publication date: October 2020Source: The Lancet Haematology, Volume 7, Issue 10Author(s): Cheedy Jaja, Robert W Gibson, Joseph Edem-Hotah
Source: The Lancet Haematology - Category: Hematology Source Type: research
Conclusion and Recommendation. Children with SCA had more impairment in terms of copying and IQ. We recommend assessment at the younger age group, increased sample size in future studies, and long-term cohort follow-up. PMID: 32953173 [PubMed]
Source: Neurology Research International - Category: Neurology Tags: Neurol Res Int Source Type: research
Authors: Meier ER PMID: 32955945 [PubMed - as supplied by publisher]
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Conclusion: The average cost for complete healing of a sickle cell ulcer with an average area of 14.95 cm2 was R$ 1,288.06.Resumen Objetivo: Identificar los costos desembolsados con el tratamiento de la úlcera de pierna consecuente de la enfermedad de células falciformes bajo la perspectiva del Sistema Único de Salud. Método: Estudio observacional, descriptivo, de evaluación económica del costo-efectividad, llevado a cabo en un centro único, con pacientes portadores de úlcera. Los datos r ecogidos fueron extraídos de la ficha del participante y registrados en f...
Source: Revista da Escola de Enfermagem da USP - Category: Nursing Source Type: research
In this study, we report the case of a previously healthy 5-year-old boy with infection-related glomerulonephritis (IRGN) associated with PVB19 that progressed to end-stage renal disease (ESRD). He presented with macrohematuria, nephrotic-range proteinuria, and progressive renal dysfunction despite treatment with methylprednisolone pulse therapy, plasmapheresis, and intravenous immunoglobulin. The kidney biopsy specimens exhibited endocapillary infiltration and mesangiolysis with cellular crescent formation. Immunofluorescence analysis revealed that IgA was dominantly positive in the glomeruli, with some co-localized with ...
Source: CEN Case Reports - Category: Urology & Nephrology Source Type: research
CONCLUSION: Flow cytometric analysis on the patient's blood samples allowed the diagnosis of Type I CD36 deficiency. CD36 antibodies, probably due to her past history of red blood cell transfusions, were identified by MAIPA and by Luminex technology assay. Interestingly, we identified through sequencing a new molecular basis involved in CD36 deficiency: two adenines were replaced by one guanine in Exon 4 (c.367_368delAAinsG) leading to a stop codon at Position 76. PMID: 32949421 [PubMed - as supplied by publisher]
Source: Transfusion - Category: Hematology Authors: Tags: Transfusion Source Type: research
Authors: Noun P, Ibrahim A, Hodroj MH, Bou-Fakhredin R, Taher AT Abstract INTRODUCTION: Many patients with inherited or acquired benign hematological disorders are at increased risk of developing severe complications from COVID-19. These patients, therefore, require specific advice regarding isolation and changes to their usual treatment schedules. Their disease can also be associated with significant burden, and they necessitate life-long and regular access to therapy, and regular follow-up consultations and hospital visits. The current COVID-19 pandemic is therefore presenting many challenges for these patients, ...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
(Critical Path Institute (C-Path)) C-Path) today announced the launch of the Critical Path for Sickle Cell Disease (CP-SCD) Consortium to support collaboration and regulatory endorsement of new medical product development tools for sickle cell disease. These tools will help to optimize and de-risk clinical trials to increase efficiency in developing and delivering safe, effective treatments for people living with sickle cell disease.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Biochemistry | Sickle Cell Anemia | Study